Eli Lilly has now firmly established itself as the leader in the market for anti-obesity drugs. However, it could solidify its position next year with a pair of new launches. First, there is ...

First, a quick reminder of the Lilly story so far. This pharma giant sells a variety of drugs across treatment areas, from neurology to dermatology. And this has helped the company offer investors ...

The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for ...

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...